MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of “Hold” by Brokerages

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) have been given an average rating of “Hold” by the sixteen ratings firms that are presently covering the firm, MarketBeat reports. Four research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $25.7692.

A number of equities research analysts recently commented on the company. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $10.00 price objective (down from $67.00) on shares of MoonLake Immunotherapeutics in a research note on Monday, September 29th. The Goldman Sachs Group lowered MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and boosted their target price for the stock from $8.00 to $10.00 in a research report on Wednesday, January 14th. Wedbush cut their price target on shares of MoonLake Immunotherapeutics from $80.00 to $18.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MoonLake Immunotherapeutics in a research note on Wednesday, October 8th. Finally, Guggenheim reduced their price target on shares of MoonLake Immunotherapeutics from $80.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, September 30th.

MoonLake Immunotherapeutics Trading Up 2.3%

MLTX opened at $16.71 on Thursday. MoonLake Immunotherapeutics has a fifty-two week low of $5.95 and a fifty-two week high of $62.75. The company has a market cap of $1.07 billion, a price-to-earnings ratio of -5.03 and a beta of 1.21. The company has a debt-to-equity ratio of 0.25, a current ratio of 8.50 and a quick ratio of 8.50. The firm has a 50 day simple moving average of $14.15 and a 200 day simple moving average of $29.78.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its earnings results on Wednesday, November 5th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.21). During the same period in the previous year, the business earned ($0.56) EPS. On average, sell-side analysts anticipate that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

Insider Activity

In other news, CEO Da Silva Jorge Santos sold 70,000 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $14.49, for a total transaction of $1,014,300.00. Following the sale, the chief executive officer owned 2,878,577 shares of the company’s stock, valued at $41,710,580.73. This trade represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kristian Reich sold 72,908 shares of MoonLake Immunotherapeutics stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $14.43, for a total value of $1,052,062.44. The disclosure for this sale is available in the SEC filing. Insiders sold 402,908 shares of company stock valued at $5,987,162 over the last 90 days. Corporate insiders own 12.02% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Schonfeld Strategic Advisors LLC bought a new stake in shares of MoonLake Immunotherapeutics during the third quarter worth $6,922,000. Two Sigma Investments LP acquired a new position in MoonLake Immunotherapeutics in the 3rd quarter worth $3,257,000. Vestal Point Capital LP boosted its stake in MoonLake Immunotherapeutics by 175.0% in the 2nd quarter. Vestal Point Capital LP now owns 550,000 shares of the company’s stock worth $25,960,000 after purchasing an additional 350,000 shares during the period. Balyasny Asset Management L.P. increased its holdings in MoonLake Immunotherapeutics by 436.8% during the 2nd quarter. Balyasny Asset Management L.P. now owns 423,170 shares of the company’s stock worth $19,974,000 after purchasing an additional 344,335 shares in the last quarter. Finally, Millennium Management LLC raised its stake in shares of MoonLake Immunotherapeutics by 3,343.2% in the 1st quarter. Millennium Management LLC now owns 344,320 shares of the company’s stock valued at $13,453,000 after purchasing an additional 334,320 shares during the period. Institutional investors and hedge funds own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.